|Articles|October 15, 2014

AbbVie Reconsiders Shire Offer

Author(s)BioPharm International Editors

AbbVie sends Shire notice that it is reconsidering its offer recommendation.

Breaking News: AbbVie/Shire Deal Is Officially Off

Reuters is reporting that AbbVie is reconsidering its acquisition of Shire as a result of US tax law proposals that would limit the ability of American companies to shift their tax bases out of the United States. AbbVie’s board will meet to discuss the impact of the US Department of Treasury changes to tax regulations on October 20. AbbVie announced its interest in Shire in July.

Shire confirmed receipt of AbbVie’s notice of its consideration to either withdraw or modify its offer recommendation in a statement on the company’s website. In the Shire statement, the Board of Shire expresses its belief that AbbVie should proceed with the recommended offer.

Stay at the forefront of biopharmaceutical innovation. Subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related to this article

October 23rd, 2026

The BioPharm Brief: Gilead’s Oral IL-23R Bet, Roche’s Trispecific Deal, and Treasury’s Biotech Investment Proposal

Gilead agrees to acquire PepStar’s oral IL-23R peptide program for $1.275 billion, Zymeworks licenses its DLL3-targeted trispecific T-cell engager ZW209 to Roche, and the US Treasury proposes adding biotechnology to its outbound investment restrictions.

3D illustration of a translucent blue human torso showing the skeleton, with pink lungs, trachea, and branching bronchi highlighted in the chest. | Image Credit: © yodiyim - stock.adobe.com

October 23rd, 2026

Zymeworks Licenses DLL3-Targeted Trispecific T-Cell Engager ZW209 to Roche in Deal Worth Up to $813 Million

Roche gains exclusive global rights to ZW209, a DLL3×CD3×CD28 trispecific T-cell engager designed for CD28 co-stimulation. A phase 1 study in small cell lung cancer and other neuroendocrine tumors is underway.

Exterior of the US Department of the Treasury building in Washington, DC, with a columned entrance, an American flag on the roof, green shrubs and a lawn in the foreground, and a clear blue sky. | Image Credit: © Jorge Moro - stock.adobe.com

October 23rd, 2026

Treasury Proposes Adding Biotech to Outbound Investment Restrictions Under COINS Act

A Treasury proposed rule would restrict certain US investments in biotechnology in China and other countries of concern, raising questions about how cross-border licensing and joint venture deals will be treated.

October 22nd, 2026

Turn Supply Chain Data Into Decisions Before Shortages Reach Patients, Says RELEX’s Rohit Tripathi

Rohit Tripathi, vice president of industry strategy, consumer packaged goods, and manufacturing at RELEX Solutions, explains where cold-chain planning still breaks down and why biopharma supply chain leaders should use AI to act on data sooner, with humans making the final call.

October 22nd, 2026

The BioPharm Brief: Kidney Approval, Retinal Cell Therapy, and a Breast Cancer Trial Shift

The FDA grants accelerated approval to Ultomiris for IgA nephropathy, Alcon acquires Neurotech and its MacTel cell therapy for $550 million, and BioNTech and Bristol Myers Squibb add Trodelvy to a phase 3 trial in triple-negative breast cancer.

3D cross-section illustration of breast tissue showing pink lobes, milk ducts converging toward the nipple, and a dark red clustered mass representing a tumor. | Image Credit: © Design cells - stock.adobe.com

October 22nd, 2026

BioNTech, BMS to Pair Pumitamig With Trodelvy in Phase 3 First-Line TNBC Trial

BioNTech and Bristol Myers Squibb will replace chemotherapy with Gilead’s TROP2-directed ADC sacituzumab govitecan in the Phase 3 ROSETTA Breast-01 trial of PD-L1×VEGF-A bispecific pumitamig in PD-L1-low or -negative TNBC.

A clinician in a white coat with a stethoscope points a pen at an anatomical model showing the kidneys, renal blood vessels, aorta, vena cava, and ureters. | Image Credit: © Yanisa - stock.adobe.com

October 22nd, 2026

FDA Grants Accelerated Approval to Ultomiris as First C5 Inhibitor for IgA Nephropathy

Alexion’s ravulizumab won accelerated approval to reduce proteinuria in adults with IgA nephropathy after the Phase 3 I CAN trial showed a 43.4% placebo-adjusted reduction at Week 34.

October 21st, 2026

The BioPharm Brief: Insulin Supply Security, a Bispecific Head-to-Head, and Long-Acting HIV Antibodies

Sanofi breaks ground on an EU-backed insulin API plant in Frankfurt, Summit and ECOG-ACRIN launch a phase 2/3 trial of ivonescimab in first-line biliary tract cancer, and TaiMed’s anti-CD4 antibody TMB-365 lowers HIV viral load in phase 1.

AbbVie Reconsiders Shire Offer

Related to this article

Trending on BioPharm International

BioNTech, BMS to Pair Pumitamig With Trodelvy in Phase 3 First-Line TNBC Trial

Zylidac Bio to Scale Prolific's Optogenetic Cell Line Platform to GMP

Treasury Proposes Adding Biotech to Outbound Investment Restrictions Under COINS Act

TaiMed’s Anti-CD4 Antibody TMB-365 Reduces HIV Viral Load in Phase 1, Supporting Long-Acting Combination Regimens

FDA Grants Accelerated Approval to Ultomiris as First C5 Inhibitor for IgA Nephropathy